This drive and discovery has shaped our legacy in immunology and will pave the way for delivering new solutions to the people we serve.
We are growing a robust pipeline with a range of new therapies that have the potential to alter treatment paradigms for such chronic conditions as multiple sclerosis, systemic lupus erythematosus, osteoarthritis and rheumatoid arthritis.
We are discovering new ways to optimize outcomes for a range of chronic progressive diseases by pursuing novel pathways that modulate the immune system in more targeted manners than traditional immunosuppressants.
For immune disorders, we develop approaches that target the innate and adaptive components of the immune system. This includes inhibiting the inappropriate immune activation that contributes to the disorder, as well as enhancing immune tolerance, which trains the body not to react to triggers.
For the treatment of forms of arthritis, our investigational therapies feature approaches that may facilitate cartilage repair homeostasis (a balance of re-growing cartilage and stopping cartilage from breaking down).
To deliver best in class therapies to patients, we are combining our significant internal scientific expertise with strategic external partnerships.
Browse the programs in our pipeline to see what we’re currently working on by phase, therapeutic area, and compound type. You can also see what we’ve discovered in-house versus those assets we’re partnering on with other giants in our industry. Learn more